End-to-end Invention at Deep Science Ventures
Elman has demonstrated significant improvements in DSV's accuracy, productivity, and creativity.
Our research shows it accelerates research tasks, reducing state-of-the-art analysis time from weeks to days and saving thousands of hours of identifying and derisking venturable scientific approaches.
In a key success with a top 3 pharma company, Elman identified an overlooked component for mRNA conditionality—now integral to their drug development pipeline—showcasing its ability to drive impactful research outcomes.